SCHEMBL25858213

SCHEMBL25858213

Cc1cc(NCCCO)nc(NC(=O)Nc2ccc(Cl)c(C)c2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
RAB9A P51151 6/20 0.43
NPC1 O15118 5/20 0.43
BLM P54132 1/20 0.41
PCTP Q9UKL6 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CNR1 P21554 3/20 0.40
KDM4E B2RXH2 2/20 0.40
TP53 P04637 2/20 0.40
GLA P06280 1/20 0.40
GBA1 P04062 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
EPHX2 P34913 2/20 0.38
EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18037995 0.93 NPC1 (0.52) KMT2ARAB9ANPC1PCTPSMN1; SMN2
SCHEMBL25858229 0.91 DNM2 (0.45) KMT2ARAB9ANPC1BLMSMN1; SMN2
SCHEMBL23258168 0.89 NPC1 (0.51) KMT2ARAB9ANPC1PCTPSMN1; SMN2
SCHEMBL18038021 0.88 CNR1 (0.48) KMT2ARAB9APCTPSMN1; SMN2CNR1
SCHEMBL18017324 0.87 ALDH1A1 (0.38) KMT2ANPC1SMN1; SMN2KDM4ETP53
SCHEMBL25858294 0.87 KMT2A (0.42) KMT2ARAB9ANPC1BLMSMN1; SMN2
SCHEMBL23258624 0.87 ALDH1A1 (0.53) KMT2ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL23258569 0.86 NPC1 (0.54) KMT2ARAB9ANPC1PCTPSMN1; SMN2
SCHEMBL25858313 0.85 SMN1; SMN2 (0.47) KMT2ARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL18038000 0.85 KMT2A (0.65) KMT2ARAB9ANPC1SMN1; SMN2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321094-A1 COMBINATION THERAPIES WITH OLIG2 INHIBITORS Curtana Pharmaceuticals, Inc. 2023-10-12 US disclosed
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2023-08-31 US disclosed
US-11691951-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691951-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG KMT2A 501/4885RAB9A 3638/4885NPC1 4224/4885
US-20230321094-A1 COMBINATION THERAPIES WITH OLIG2 INHIBITORS PAX2, GLI2, RUNX1 KMT2A 337/4885RAB9A 4088/4885NPC1 3251/4885
US-20230271926-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG KMT2A 501/4885RAB9A 3638/4885NPC1 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.